Elanco Animal Health Incorporated (NYSE:ELAN) reported stronger-than-expected third-quarter 2026 earnings and revenue, prompting the animal healthcare company to increase its full-year financial guidance. Shares climbed 7.6% following the announcement.
Adjusted earnings reached $0.27 per share, exceeding analysts’ consensus estimate of $0.21. Revenue increased 11% year over year to $1.26 billion, ahead of expectations of $1.21 billion. On an organic constant-currency basis, sales grew 9%.
The results reflected growth across Elanco’s Pet Health and Farm Animal businesses, supported by demand for newer products, improved pricing and higher operating margins.
Pet Health Sales Rise 14% as Profitability Improves
Elanco’s Pet Health division generated revenue of $608 million, an increase of 14% from the previous year, driven by strong demand for Zenrelia and Credelio Quattro.
Farm Animal revenue rose 6% to $631 million, contributing to the company’s overall sales growth.
Adjusted gross margin expanded by 300 basis points to 56.1%, exceeding expectations as higher pricing and a favourable product mix supported profitability.
Adjusted EBITDA increased 23% year over year to $243 million, while the adjusted EBITDA margin improved to 19.5% from 17.5% in the corresponding quarter of 2025.
Elanco also reduced its net leverage ratio to 2.9 times adjusted EBITDA, achieving the milestone earlier than management had anticipated.
President and Chief Executive Officer Jeff Simmons highlighted the company’s improving financial performance.
“Our third-quarter performance demonstrates Elanco’s ability to deliver consistent, dependable growth through its diversified portfolio of innovative products, while accelerating cash flow generation,” Simmons said.
Elanco Raises Full-Year Revenue and Earnings Guidance
Following the quarterly earnings beat, Elanco increased its adjusted earnings forecast for 2026 to between $1.17 and $1.20 per share, compared with its previous guidance of $1.10 to $1.16.
The revised midpoint of approximately $1.19 exceeds analysts’ consensus estimate of $1.13.
The company also raised its full-year revenue outlook to between $5.15 billion and $5.18 billion, up from the previous range of $5.09 billion to $5.14 billion.
The new revenue guidance midpoint of approximately $5.17 billion is above the market consensus of $5.13 billion.
The increases reflect management’s expectations for continued sales growth and improved profitability across the business.
Fourth-Quarter Outlook Points to Continued Growth
For the fourth quarter of 2026, Elanco expects revenue of between $1.19 billion and $1.22 billion, with adjusted earnings of $0.16 to $0.19 per share.
The company’s improved annual outlook follows stronger demand for its animal health products, expanding margins and progress in reducing leverage.
The 7.6% share price increase reflected investors’ positive response to the earnings beat and upward revisions to guidance.
Looking ahead, Elanco’s performance will depend on sustaining demand across its Pet Health and Farm Animal divisions while maintaining pricing discipline, profitability improvements and cash flow generation.